Tenofovir Alafenamide Fumarate Microspheres, Process Parameters for Enhanced Permeability and Liver Targeting

K. Sudhamani *

Department of pharmaceutics, Mallareddy Institute of Pharmaceutical Sciences, Affiliated to JNTUH, Hyderabad, Telangana, India.

B. Jeevana Jyothi

Department of pharmaceutics, Institute of Pharmaceutical Technology, Tirupati, Andhra Pradesh, India.

*Author to whom correspondence should be addressed.


Abstract

Aims: Chronic hepatitis B (CHB) infection is a serious global health problem and one of the main causes of chronic liver disease, cirrhosis. Tenofovir Alafenamide Fumarate (TAF) is a prodrug of Tenofovir, a nucleotide analogue with limited oral bioavailability. TAF is considered to be a BCS Class III substance (high solubility, low permeability). The aim of the study was to develop the Tenofovir Alafenamide Fumarate (TAF) microspheres to improve permeability.

Study design: Preparation and Evaluation of Microspheres.

Place and Duration of Study: Department of pharmaceutics, Mallareddy Institute of Pharmaceutical Sciences, Affiliated to JNTUH, Hyderabad, Telangana, India, between January 2018 and June 2019.

Methodology: TAF loaded chitosan microspheres were prepared by emulsion cross linking method using glutaraldehyde as cross-linking agent. The prepared microspheres were characterized by morphology, size distribution, encapsulation efficiency. The permeability study was evaluated by Ex-vivo permeation studies. The optimized formulation was subjected to FTIR studies to examine the Drug Excipient Compatibility.

Results: Scanning Electron Microscopy (SEM) studies indicated that the microspheres are spherical in shape. The optimized formulation has average particle size of 11.00 ± 0.05 µm, the encapsulation efficiency 68

± 0.04% and the percentage (%) yield of 94%. FTIR studies indicated that the drug and polymer are compatable with each other. In Ex-vivo permeation studies of optimized formulation 80% of drug was permeated with in 60 min.

Conclusion: TAF microspheres could improve the absorption by increasing the permeability.

Keywords: Microspheres, emulsion cross linking, glutaraldehyde and Tenofovir Alafenamide Fumarate (TAF)


How to Cite

Sudhamani, K. and Jyothi, B. J. (2021) “Tenofovir Alafenamide Fumarate Microspheres, Process Parameters for Enhanced Permeability and Liver Targeting”, Journal of Pharmaceutical Research International, 33(41A), pp. 187–196. doi: 10.9734/jpri/2021/v33i41A32317.